Uni-Bio Science Group Limited 2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 million Recording EBITDA of HK$28.4 million Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020
(Stock code: 0690)
Uni-Bio Science Group Limited 2019 Annual Results
Turnover Increased by 54.9% YoY to HK$209.4 million
Recording EBITDA of HK$28.4 million
Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020
[31 March 2020 - Hong Kong] A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2019 (the "Year"), as well as its comparatively figures for the year ended 31 December 2018 ("2018").
Key Accomplishments in 2019
During the Year, the Group has recorded a spectrum of accomplishments both in terms of marketed products, and consolidation of the Group's assets. The key highlights include:
In 2019, the Group recorded a turnover of HK$209.4 million, representing a surge of approximately 54.9% YoY (2018: HK$135.3 million). The increase in turnover was mainly attributable to the significant sales growth of GeneTime(R) and the rebound in sales of Pinup(R). Among all the products, GeneTime(R) was particularly favoured by the market, with an increase of 103.2% from approximately HK$63.0 million in 2018 to HK$128 million in 2019. GeneSoft(R) recorded a stable revenue growth from approximately HK$27.1 million to HK$30 million, representing an increase of 10.7%. The growth was mainly attributable to our strategic cooperation with CR Zizhu to broaden our distribution channels. With new strategy in place and good progress of the bioequivalent ("BE") study, Pinup(R) revenue surged by 58.2% from approximately HK$29.4 million to approximately HK$46.5 million in 2019. The Group expects that Pinup(R) will be the second BE approved voriconazole in the market.
Cost of sales for the Year increased proportionally by 58.2% from HK$17.7 million in 2018 to HK$27.9 million in 2019. Gross profit increased 54.3% from approximately HK$117.6 million in 2018 to HK$181.5 million in 2019, mainly driven by the increase in revenue. On the contrary, gross profit margin remained stable at 86.7% (2018: 86.9%). Alongside our efforts of restructuring and reorganizing our direct sales team to achieve greater efficiency, selling and distribution costs as a percentage to revenue decreased from 85.8% in 2018 to 71.3% in 2019, representing a decrease of 14.5 percentage points. The Group's structure has changed from a divisional organization structure to a functional organization structure with specific business units, which led to additional savings and efficiencies by combining supporting functions into one. Substantial saving has been seen from such restructuring with general and administrative expenses decreased by 20.6% from HK$74.8 million in 2018 to HK$59.4 million in 2019. The Group continued to focus on research and development by investing HK$42.7 million in 2019, which was approximately the same as HK$44.2 million in 2018. With the strong revenue growth and stringent cost and expenses control measures, the Group achieved profitability this year, demonstrating the effectiveness of the our strategies. As compared with the loss of approximately HK$107.9 million for the year ended 31 December 2018, the Group recorded an earnings before interest, tax, depreciation and amortization of approximately HK$28.4 million as at 31 December 2019. Profit for the year amounted to HK$2.5 million with basic earnings per share of HK$0.04 cents, marking a turnaround from a loss of HK$138.6 million or a basic loss per share of HK2.24 cents in 2018.
China's pharmaceutical market has been growing in recent years and is estimated to reach $161.8 billion in size by 2023, or 30% of the global market. The industry has slowly shifted its focus from generic drugs to the development of original and innovative treatment. To reduce the reliance on imports, the Central Government has introduced a series of policies, some of which included developing multinational clinical centres, sharing clinical data globally, accelerating the approval process of innovative medicine, and enhancing the protection of clinical data. The drug approval speed has since increased by 62%, while the newly approved biologicals in 2018 have also surged by 450% YoY.
The State Council introduced a new arrangement for the state-organized, centralized procurement reform ("4+7 pilot programme"). This included expanding the pilot area for the centralized procurement and use of generic drugs to almost the entire mainland, covering 11 major cities including Shanghai and Beijing, as well as increasing the drug varieties. It is expected that in the next 3 years, 80% of the top selling drugs (oral intake) will be included in the 4+7 pilot programme. Acarbose has already been included in the list and there is a possibility that Pinup(R) may also be included within the next 3 years.
Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, "Adhering to our strategic plan, in 2019, the Group has invested heavily on the research and development of medicines in areas of chronic metabolic disorder, such as diabetes and osteoporosis, as well as epidermal growth factors. In face of the growing ageing population, we collaborated with Kai Ping Shi Jian Bao Zhen Tourism Development Company Limited to co-construct healthcare facilities to treat the increasing needs of patients with chronic disease. We believe that this cooperation will greatly benefit our Uni-E4 and Uni-PTH development and further enhance our technical knowledge in the field of diabetes and osteoporosis. The positive feedback received from CDE and NMPA has ensured our pipeline products will be launched as scheduled and has solidified our competition advantages in the market. In response to the 4+7 pilot programme, we are actively looking for strategic partners, particularly on our generic product line in order to optimize manufacturing cost and yield a higher competitive advantage for our products. In the short term, we remain razor focused in pushing forward our drug application process, establishing strategic partnerships, as well as further optimizing our sales and marketing structure. In the mid-to-long term, we will leverage on our core strength of innovative biologic R&D, in particular look towards building a pipeline of best-in-class candidates, and less focused on generics, in hope to create a fruitful return for our shareholders."
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments and innovative drugs addressing the therapeutic areas of diabetes, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
This press release is issued by DLK Advisory Limited for and on behalf of Uni-Bio Science Group Limited.
For further information, please contact:
Company Secretary : Richard She (Shen Zhen)
IR: Henry Leung (Hong Kong )
Document title: Uni-Bio Science Group Limited 2019 Annual Results Turnover Increased by 54.9% YoY to HK$209.4 million Recording EBITDA of HK$28.4 million Achieved Significant Progress towards Pipeline Product with 2 Product Launches Expected in 2020
01/04/2020 Dissemination of a Marketing Press Release, transmitted by EQS Group.